| n/N (b) | Percentage |  |
---|---|---|---|
Anti-Tat cellular response in vaccinees (a) | Â | Â | Â |
IgM+ and IgG+ | 60/67 | 89.5 | Â |
IgM+, IgG+ or IgA+ | 34/40 | 85.0 | Â |
Ab Negative | 22/29 | 75.9 | Â |
HIV-1 DNA (log 10 copies/10 6 CD4 + T cells) | Year (c) | Mean ± s.e. (d) | n |
Vaccinees | Â | Â | Â |
Anti-Tat Ab negative and cellular positive | Â | Â | Â |
 | 2nd | −0.08 ± 0.09 | 21 |
 | 3rd | −0.21 ± 0.11 | 11 |
 | 2nd and 3rd | −0.08 ± 0.08 | 22 |
Anti-Tat Ab negative and cellular negative | Â | Â | Â |
 | 2nd | 0.09 ± 0.14 | 7 |
 | 3rd | 0.10 ± 0.57 | 3 |
 | 2nd and 3rd | 0.06 ± 0.17 | 7 |
OBS subjects(e) | Â | Â | Â |
Anti-Tat Ab negative and cellular positive | |||
 | 2nd | −0.12 ± 0.07 | 37 |
 | 3rd | −0.16 ± 0.07(*) | 28 |
 | 2nd and 3rd | −0.13 ± 0.07 | 37 |
Anti-Tat Ab negative and cellular negative | Â | Â | Â |
 | 2nd | −0.07 ± 0.07 | 8 |
 | 3rd | 0.09 ± 0.12 | 8 |
 | 2nd and 3rd | 0.00 ± 0.05 | 8 |